Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies

Diagnostic Microbiology and Infectious Disease

Volumn 68, Issue 3, 2010, Pages 326-329

  Keel, Rebecca A ^a   Sutherland, Christina A ^a   Aslanzadeh, Jaber ^b   Nicolau, David P ^a,b   Kuti, Joseph L ^a  

^a Center for Anti Infective Research and Development   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Broth microdilution; Daptomycin; E test; MIC; MicroScan; Staphylococcus aureus; Vancomycin

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; CORRELATION COEFFICIENT; EPSILOMETER TEST; INTERMETHOD COMPARISON; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 77957929249     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.08.006     Document Type: Article

References (22)

1. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 19th information supplement (M100-S19) 2009, CLSI, Wayne, PA.
2. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition, M07-A8 2009, CLSI, Wayne, PA.
3. Cui L., Tominaga E., Neoh H., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50:1079-1082.
4. Hidayat L.K., Dl H., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 2006, 166:2138-2144.
5. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., Grabsch E.A., Roberts S.A., Robson J., Read K., Bak N., Hurley J., Johnson P.D., Morris A.J., Mayall B.C., Grayson M.L. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004, 38:521-528.
6. Hsu D.I., Hidayat L.K., Quist R., Hindler J., Karlsson A., Yusof A., Wong-Beringer A. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 2008, 32:378-385.
7. Jevitt L.A., Smith A.J., Williams P.P., Raney P.M., Mcgowan J.E., Tenover F.C. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. 2003, 9:389-393.
8. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 2006, 42:S13-S24.
9. Lodise T.P., Graves J., Graffunder E., Helmecke M., Lomaestro B.M., Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 2008, 52:3315-3320.
10. Mason E.O., Lamberth L.B., Hammerman W.A., Hulten K.G., Versalovic J., Kaplan S.L. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J. Clin. Microbiol. 2009, 47:1628-1630.
11. Neoh H., Hori S., Komatsu M., Oguri T., Takeuchi F., Cui L., Hiramatsu K. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 2007, 6:13.
12. Patel N., Lubanski P., Ferro S., Bonafede M., Harrington S., Evans A., Stellrecht K., Lodise T.P. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53:5141-5144.
13. Pillai S.K., Wennersten C., Venkataraman L., Eliopoulos G.M., Moellering R.C., Karchmer A.W. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin. Infect. Dis. 2009, 49:1169-1174.
14. Rhee K.Y., Gardiner D.F., Charles M. Decreasing in-vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin. Infect. Dis. 2005, 40:1705-1706.
15. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., Dalovisio J.R., Levine D.P. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 2009, 66:82-98.
16. Sader H.S., Jones R.N. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin. Infect. Dis. 2006, 43:798-799.
17. Sader H.S., Fey P.D., Fish D.N., Limaye A.P., Pankey G., Rahal J., Rybak M.J., Snydman D.R., Steed L.L., Waites K., Jones R.N. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 2009, 53:4127-4132.
18. Sader H.S., Rhomberg P.R., Jones R.N. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53:3162-3165.
19. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering R.C., Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 2006, 50:1581-1585.
20. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., Alamo D., Ortega M., Lopez J., Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46:193-200.
21. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 2007, 60:788-794.
22. Wang G., Hindler J.F., Ward K.W., Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 2006, 44:3883-3886.